On page 27-28 of the English translation of the specification, please amend claim 1 to read as follows:

1. A compound of having the chemical structure of formula (A):



(A)

with peripheral analgesic effect, wherein:

a) X is selected from the group consisting of H and C_{1-6} alkyl;

b) Y and Z are independently selected from the group consisting of H, cyclic aralkyl, and C_{1-6} alkyl;

c) R_1 is a tyrosyl residue or a 2',6'-dimethyltyrosyl residue;

d) R_2 is an amino acid having the R-configuration, aminoisobutyric acid, cyclopropylalanine, cyclohomoleucine or cycloleucine;

e) R_3 is an aromatic amino acid;

f) R_4 is an aromatic amino acid residue;

g) Q is an amide bond or an interposed amide bond mimetic;

h) with the proviso that when:

i) R_1 is a tyrosyl residue;

ii) R_2 is D-alanine;

iii) X, Y, and Z are H; and

iv) R_3 is phenylalanine;

then R_4 is not unsubstituted phenylalanine or phenylalanine substituted with $4NO_2$ or $4N_3$;

i) with the further proviso that when:

i) R_1 is a tyrosyl residue;

ii) R_2 is D-alanine;

iii) X, Y, and Z are H; and

iv) R_3 is phenylalanine;

j) with the further proviso that when:

i) R_1 is a tyrosyl residue;

ii) R_2 is D-alanine;

iii) X, Y, and Z are H; and

iv) R_4 is 1'-naphthylalanine;

then R_3 is not 1'-naphthylalanine or 2'-naphthylalanine;

k) with the further proviso that when:

i) R_1 is a tyrosyl residue;

ii) R_2 is D-alanine; and

iii) X, Y and Z are H,

then both R_3 and R_4 are not tryptophan;

l) with the further proviso that when:

i) R_1 is a tyrosyl residue;

ii) R_2 is a D-amino acid with a lower alkyl or lower thioalkyl group as a side chain; and

iii) R_4 is a neutral amino acid,

then R_3 is not unsubstituted phenylalanine;

m) and wherein said compound is not selected from the group consisting of:

H-Tyr-D-Phe-Phe-Phe-NH_2;

H-Tyr-D-NMePhe-Phe-Phe-NH_2;

H-Tyr-D-Tic-Phe-Phe-NH_2;

H-Tyr-Pro-Phe-Thr(Bz1)-NH_2; (SEQ ID NO:2)

H-Tyr-Pro-Phe-Phe-NH_2; (SEQ ID NO:1)

H-Tyr-Pro-Phe-Apb-NH_2;

H-Tyr-Pro-Phe-App-NH_2;

H-Tyr-Pro-Phe-Aph-NH_2; and

H-Tyr-Pro-Apb-Phe-NH_2;

wherein Apb is 2-amino-4-phenylbutanoic acid, App is 2-amino-5-phenylpentanoic acid and Aph is 2-amino-6-phenylhexanoic acid.

to read as follows:

15. A compound selected from the group consisting of:

H-Tyr-Aib-Phe-Phe-NH_2;

H-Tyr-D-Nle-Phe-Phe-NH_2;

H-Tyr-D-Ala-Phe-2'-Nal-NH_2;

H-Tyr-D-Ala-D-Phe-Phe-NH_2;

H-Tyr-D-Ala-Phe($4NO_2$)-Phe($4NO_2$)-NH_2;

H-Tyr-D-Ala-Phe-Tic-NH_2;

H-Tyr-D-Ala-Phe-Phe(NMe)-NH_2;

H-Tyr-D-Ala-Phe-1'-Nal-NH_2;

H-Tyr-D-Ala-Trp-Phe-NH_2;

H-Tyr-D-Ala-Phe-Trp-NH_2;

H-Tyr-∇Ala-Phe-Phe-NH_2; (SEQ ID NO:3)

∇CH_2-Tyr-D-Ala-Phe-Phe-NH_2;

H-Tyr-D-Nle-Phe-Trp-NH_2;

H-Tyr-D-Nle-Phe-2'-Nal-NH_2;

H-Tyr-D-Nle-Trp-Phe-NH_2;

H-Tyr-D-Ala-Trp-2'-Nal-NH_2;

H-Tyr-D-Nle-Trp-2'-Nal-NH_2;

H-Tyr-D-Nle-Trp-Trp-NH_2;

H-Tyr-D-Nva-Phe-Phe-NH_2;

H-Tyr-D-Ser-Phe-Phe-NH_2;

H-Tyr-D-Val-Phe-Phe-NH_2;

H-Tyr-D-Leu-Phe-Phe-NH_2;

H-Tyr-D-Ile-Phe-Phe-NH_2;

H-Tyr-D-Abu-Phe-Phe-NH_2;

H-Tyr-Chl-Phe-Phe-NH_2;

H-Tyr-Cle-Phe-Phe-NH_2;

H-Tyr-D-Arg-Phe-Phe-NH_2;

H-Tyr-D-Cys-Phe-Phe-NH_2;

H-Tyr-D-Ala-Phe-Phe-OH trifluoroacetate;

H-Tyr-D-Ala-Phe-Phg-NH_2 trifluoroacetic acid salt;

H-Tyr-D-Arg-Phe-Hph-NH_2 bis-trifluoroacetic acid;

H-DMT-D-Ala-Phe-Phe-NH_2 trifluoroacetic acid;

H-D-DMT-D-Ala-Phe-Phe-NH_2 trifluoroacetic acid salt;

H-Tyr-D-Ala-Phe-Hph-NH_2 trifluoroacetic acid salt;

H-Tyr-D-Ala-Phe-Cys(Bzl)-NH_2 trifluoroacetic acid salt;

H-Tyr-D-Arg-Hph-Phe-NH_2 bis-trifluoroacetic acid salt;

H-Tyr-D-Arg-Phg-Phe-NH_2 bis-trifluoro acetic acid salt;

H-Tyr-D-Ala-Phe-Phe-CH_2OH hydrochloride salt;

H-Tyr-D-Ala-Hph-Phe-NH_2 trifluoroacetic acid salt;

H-Tyr-D-Met-Phe-Phe-NH_2 trifluoroacetic acid salt;

H-Tyr-D-Arg-Phe-D-Phe-NH_2 bis-trifluoroacetic acid salt;.

H-Tyr-D-Ala-Phg-Phe-NH_2 trifluoroacetic acid salt;

H-Tyr-(D)-Ala-(D)-Phg-Phe-NH_2 trifluoroacetic acid salt;

H-Tyr-D-Arg-Phe-Phe(pF)-NH_2 bis-trifluoroacetic acid salt;

H-Tyr-D-Arg-Phe-D-Phe(pF)-NH_2 ditrifluoroacetic acid salt;

H-Tyr-D-Ala-Phe-Phe(pF)-NH_2 trifluoroacetic acid salt; and

H-Tyr-D-Ala-Phe-D-Phe(pF)-NH_2 trifluoroacetic acid salt.

On page 33-35 of the English translation of the specification, please amend claim 18 to read as follows:

18. A pharmaceutical composition possessing analgesic activity, comprising, in admixture with a pharmaceutically acceptable carrier, an effective amount of a least one compound having the chemical structure of formula (A):



(A)

with peripheral analgesic effect, wherein:

cyclic aralkyl, and C... alkyl;

c) R_1 is a tyrosyl residue or a 2',6'-dimethyltyrosyl residue;

d) R_2 is an amino acid having the R-configuration, aminoisobutyric acid, cyclopropylalanine, cyclohomoleucine or cycloleucine;

e) R_3 is an aromatic amino acid;

f) R_4 is an aromatic amino acid residue;

g) Q is an amide bond or an interposed amide bond mimetic;

h) with the proviso that when:

i) R_1 is a tyrosyl residue;

ii) R_2 is D-alanine;

iii) X, Y, and Z are H; and

iv) R_3 is phenylalanine;

then R_4 is not unsubstituted phenylalanine or phenylalanine substituted with $4NO_2$ or $4N_3$;

i) with the further proviso that when:

i) R_1 is a tyrosyl residue;

ii) R_2 is D-alanine;

iii) X, Y, and Z are H; and

iv) R_4 is phenylalanine;

then R_3 is not unsubstituted phenylalanine or phenylalanine substituted with $4NO_2$;

j) with the further proviso that when:

i) R_1 is a tyrosyl residue;

ii) R_2 is D-alanine;

iii) X, Y, and Z are H; and

iv) R_4 is 1'-naphthylalanine;

then R_3 is not 1'-naphthylalanine or 2'-naphthylalanine;

k) with the further proviso that when:

i) R_1 is a tyrosyl residue;

ii) R_2 is D-alanine; and

iii) X, Y and Z are H.

i) R_1 is a tyrosyl residue;

ii) R_2 is a D-amino acid with a lower alkyl or lower thioalkyl group as a side chain; and

iii) R_4 is a neutral amino acid,

then R_3 is not unsubstituted phenylalanine;

m) and wherein said compound is not selected from the group consisting of:

H-Tyr-D-Phe-Phe-Phe-NH_2;

H-Tyr-D-NMePhe-Phe-Phe-NH_2;

H-Tyr-D-Tic-Phe-Phe-NH_2;

H-Tyr-Pro-Phe-Thr(Bzl)-NH_2; (SEQ ID NO:2)

H-Tyr-Pro-Phe-Phe-NH_2; (SEQ ID NO:1)

H-Tyr-Pro-Phe-Apb-NH_2;

H-Tyr-Pro-Phe-App-NH_2;

H-Tyr-Pro-Phe-Aph-NH_2; and

H-Tyr-Pro-Apb-Phe-NH_2;

wherein Apb is 2-amino-4-phenylbutanoic acid, App is 2-amino-5-phenylpentanoic acid and Aph is 2-amino-6-phenylhexanoic acid.

On page 38-40 of the English translation of the specification, please amend claim 30 to read as follows:

30. A method for the treatment of pain comprising the step of administering to a mammal in need of such treatment a pharmaceutically effective amount of at least one compound having the chemical structure of formula (A):



(A)

wherein:

a) X is selected from the group consisting of H and C_{1-6} alkyl;

c) R_1 is a tyrosyl residue or a 2,6-dimethyltyrosyl residue;

d) R_2 is an amino acid having the R-configuration, aminoisobutyric acid,

cyclopropylalanine, cyclohomoleucine or cycloleucine;

e) R_3 is an aromatic amino acid;

f) R_4 is an aromatic amino acid residue;

g) Q is an amide bond or an interposed amide bond mimetic;

h) with the proviso that when:

i) R_1 is a tyrosyl residue;

ii) R_2 is D-alanine;

iii) X, Y, and Z are H; and

iv) R_3 is phenylalanine;

then R_4 is not unsubstituted phenylalanine or phenylalanine substituted with $4NO_2$ or $4N_3$;

i) with the further proviso that when:

i) R_1 is a tyrosyl residue;

ii) R_2 is D-alanine;

iii) X, Y, and Z are H; and

iv) R_4 is phenylalanine;

then R_3 is not unsubstituted phenylalanine or phenylalanine substituted with $4NO_2$;

j) with the further proviso that when:

i) R_1 is a tyrosyl residue;

ii) R_2 is D-alanine;

iii) X, Y, and Z are H; and

iv) R_4 is 1'-naphthylalanine;

then R_3 is not 1'-naphthylalanine or 2'-naphthylalanine;

k) with the further proviso that when:

i) R_1 is a tyrosyl residue;

ii) R_2 is D-alanine; and

iii) X, Y and Z are H,

then both R_3 and R_4 are not tryptophan;

ii) R_2 is a D-amino acid with a lower alkyl or lower thioalkyl

group as a side chain; and

iii) R_4 is a neutral amino acid,

then R_3 is not unsubstituted phenylalanine;

m) and wherein said compound is not selected from the group consisting of:

H-Tyr-D-Phe-Phe-Phe-NH_2;

H-Tyr-D-NMePhe-Phe-Phe-NH_2;

H-Tyr-D-Tic-Phe-Phe-NH_2;

H-Tyr-Pro-Phe-Thr(Bzl)-NH_2; (SEQ ID NO:2)

H-Tyr-Pro-Phe-Phe-NH_2; (SEQ ID NO:1)

H-Tyr-Pro-Phe-Apb-NH_2;

H-Tyr-Pro-Phe-App-NH_2;

H-Tyr-Pro-Phe-Aph-NH_2; and

H-Tyr-Pro-Apb-Phe-NH_2;

wherein Apb is 2-amino-4-phenylbutanoic acid, App is 2-amino-5-phenylpentanoic acid and Aph is 2-amino-6-phenylhexanoic acid.

On page 41-43 of the English translation of the specification, please amend Claim 37 to read as follows:

37. A method for the treatment of pain comprising the step of administering to a mammal in need of such treatment a pharmaceutically effective amount of a pharmaceutical composition possessing analgesic activity, wherein said pharmaceutical composition comprises, in admixture with a pharmaceutically acceptable carrier, an effective amount of at least one compound having the chemical structure of formula (A):

$$X—R_1—R_2—R_3—Q—R_4—N\begin{pmatrix} Y \\ Z \end{pmatrix}$$

(A)

[illegible]

[illegible]

cyclic aralkyl, and C_{1-6} alkyl;

c) R_1 is a tyrosyl residue or a 2',6'-dimethyltyrosyl residue;

d) R_2 is an amino acid having the R-configuration, aminoisobutyric acid, cyclopropylalanine, cyclohomoleucine or cycloleucine;

e) R_3 is an aromatic amino acid;

f) R_4 is an aromatic amino acid residue;

g) Q is an amide bond or an interposed amide bond mimetic;

h) with the proviso that when:

i) R_1 is a tyrosyl residue;

ii) R_2 is D-alanine;

iii) X, Y, and Z are H; and

iv) R_3 is phenylalanine;

then R_4 is not unsubstituted phenylalanine or phenylalanine substituted with

$4NO_2$ or $4N_3$;

i) with the further proviso that when:

i) R_1 is a tyrosyl residue;

ii) R_2 is D-alanine;

iii) X, Y, and Z are H; and

iv) R_4 is phenylalanine;

then R_3 is not unsubstituted phenylalanine or phenylalanine substituted with $4NO_2$;

j) with the further proviso that when:

i) R_1 is a tyrosyl residue;

ii) R_2 is D-alanine;

iii) X, Y, and Z are H; and

iv) R_4 is 1'-naphthylalanine;

then R_3 is not 1'-naphthylalanine or 2'-naphthylalanine;

k) with the further proviso that when:

i) R_1 is a tyrosyl residue;

then both R_3 and R_4 are not tryptophan.

l) with the further proviso that when:

i) R_1 is a tyrosyl residue;

ii) R_2 is a D-amino acid with a lower alkyl or lower thioalkyl group as a side chain; and

iii) R_4 is a neutral amino acid,

then R_3 is not unsubstituted phenylalanine;

m) and wherein said compound is not selected from the group consisting of:

H-Tyr-D-Phe-Phe-Phe-NH_2;

H-Tyr-D-NMePhe-Phe-Phe-NH_2;

H-Tyr-D-Tic-Phe-Phe-NH_2;

H-Tyr-Pro-Phe-Thr(Bzl)-NH_2; (SEQ ID NO:2)

H-Tyr-Pro-Phe-Phe-NH_2; (SEQ ID NO:1)

H-Tyr-Pro-Phe-Apb-NH_2;

H-Tyr-Pro-Phe-App-NH_2;

H-Tyr-Pro-Phe-Aph-NH_2; and

H-Tyr-Pro-Apb-Phe-NH_2;

wherein Apb is 2-amino-4-phenylbutanoic acid, App is 2-amino-5-phenylpentanoic acid and Aph is 2-amino-6-phenylhexanoic acid.

On page 46-47 of the English translation of the specification, please amend claim 51 to read as follows:

51. A pharmaceutical composition having analgesic activity, comprising in admixture with a pharmaceutically acceptable carrier, an effective amount of at least one peptide selected from the group consisting of:

H-Tyr-Aib-Phe-Phe-NH_2;

H-Tyr-D-Nle-Phe-Phe-NH_2;

H-Tyr-D-Ala-Phe-2'-Nal-NH_2;

H-Tyr-D-Ala-D-Phe-Phe-NH_2;

H-Tyr-D-Ala-Phe-Phe(NMe)-NH_2;

H-Tyr-D-Ala-Phe-1'Nal-NH_2;

H-Tyr-D-Ala-Trp-Phe-NH_2;

H-Tyr-D-Ala-Phe-Trp-NH_2;

H-Tyr-∇Ala-Phe-Phe-NH_2; (SEQ ID NO:3)

∇CH_2-Tyr-D-Ala-Phe-Phe-NH_2;

H-Tyr-D-Nle-Phe-Trp-NH_2;

H-Tyr-D-Nle-Phe-2'-Nal-NH_2;

H-Tyr-D-Nle-Trp-Phe-NH_2;

H-Tyr-D-Ala-Trp-2'-Nal-NH_2;

H-Tyr-D-Nle-Trp-2'-Nal-NH_2;

H-Tyr-D-Nle-Trp-Trp-NH_2;

H-Tyr-D-Nva-Phe-Phe-NH_2;

H-Tyr-D-Ser-Phe-Phe-NH_2;

H-Tyr-D-Val-Phe-Phe-NH_2;

H-Tyr-D-Leu-Phe-Phe-NH_2;

H-Tyr-D-Ile-Phe-Phe-NH_2;

H-Tyr-D-Abu-Phe-Phe-NH_2;

H-Tyr-Chl-Phe-Phe-NH_2;

H-Tyr-Cle-Phe-Phe-NH_2;

H-Tyr-D-Arg-Phe-Phe-NH_2;

H-Tyr-D-Cys-Phe-Phe-NH_2;

H-Tyr-D-Thr-Phe-Phe-NH_2;

H-DMT-D-Ser-Phe-Phe-NH_2;

H-Tyr-D-Ala-Phe-Phe-OH trifluoroacetate;

H-Tyr-D-Ala-Phe-Phg-NH_2 trifluoroacetic acid salt;

H-Tyr-D-Arg-Phe-Hph-NH_2 bis-trifluoroacetic acid;

H-DMT-D-Ala-Phe-Phe-NH_2 trifluoroacetic acid;

H-D-DMT-D-Ala-Phe-Phe-NH_2 trifluoroacetic acid salt;

H-Tyr-D-Ala-Phe-Hph-NH_2 trifluoroacetic acid salt;

H-Tyr-D-Arg-Phg-Phe-NH_2 bis-trifluoro acetic acid salt;

H-Tyr-D-Ala-Phe-Phe-CH_2OH hydrochloride salt;

H-Tyr-D-Ala-Hph-Phe-NH_2 trifluoroacetic acid salt;

H-Tyr-D-Met-Phe-Phe-NH_2 trifluoroacetic acid salt;

H-Tyr-D-Arg-Phe-D-Phe-NH_2 bis-trifluoroacetic acid salt;

H-Tyr-D-Ala-Phg-Phe-NH_2 trifluoroacetic acid salt;

H-Tyr-(D)-Ala-(D)-Phg-Phe-NH_2 trifluoroacetic acid salt;

H-Tyr-D-Arg-Phe-Phe(pF)-NH_2 bis-trifluoroacetic acid salt;

H-Tyr-D-Arg-Phe-D-Phe(pF)-NH_2 ditrifluoroacetic acid salt;

H-Tyr-D-Ala-Phe-Phe(pF)-NH_2 trifluoroacetic acid salt; and

H-Tyr-D-Ala-Phe-D-Phe(pF)-NH_2 trifluoroacetic acid salt.

On page 48-49 of the English translation of the specification, please amend claim 55 to read as follows:

55. A method for the treatment of pain, comprising the step administering to a mammal in need of such treatment a pharmaceutically effective amount of a peptide selected from the group consisting of:

H-Tyr-Aib-Phe-Phe-NH_2;

H-Tyr-D-Nle-Phe-Phe-NH_2;

H-Tyr-D-Ala-Phe-2'-Nal-NH_2;

H-Tyr-D-Ala-D-Phe-Phe-NH_2;

H-Tyr-D-Ala-Phe(4NO_2)-Phe(4NO_2)-NH_2;

H-Tyr-D-Ala-Phe-Tic-NH_2;

H-Tyr-D-Ala-Phe-Phe(NMe)-NH_2;

H-Tyr-D-Ala-Phe-1'Nal-NH_2;

H-Tyr-D-Ala-Trp-Phe-NH_2;

H-Tyr-D-Ala-Phe-Trp-NH_2;

H-Tyr-∇Ala-Phe-Phe-NH_2; (SEQ ID NO:3)

∇CH_2-Tyr-D-Ala-Phe-Phe-NH_2;

H-Tyr-D-Nle-Phe-Trp-NH_2;

H-Tyr-D-Ala-Trp-2'-Nal-NH_2;

H-Tyr-D-Nle-Trp-2'-Nal-NH_2;

H-Tyr-D-Nle-Trp-Trp-NH_2;

H-Tyr-D-Nva-Phe-Phe-NH_2;

H-Tyr-D-Ser-Phe-Phe-NH_2;

H-Tyr-D-Val-Phe-Phe-NH_2;

H-Tyr-D-Leu-Phe-Phe-NH_2;

H-Tyr-D-Ile-Phe-Phe-NH_2;

H-Tyr-D-Abu-Phe-Phe-NH_2;

H-Tyr-Chl-Phe-Phe-NH_2;

H-Tyr-Cle-Phe-Phe-NH_2;

H-Tyr-D-Arg-Phe-Phe-NH_2;

H-Tyr-D-Cys-Phe-Phe-NH_2;

H-Tyr-D-Thr-Phe-Phe-NH_2;

H-DMT-D-Ser-Phe-Phe-NH_2;

H-Tyr-D-Ala-Phe-Phe-OH trifluoroacetate;

H-Tyr-D-Ala-Phe-Phg-NH_2 trifluoroacetic acid salt;

H-Tyr-D-Arg-Phe-Hph-NH_2 bis-trifluoroacetic acid;

H-DMT-D-Ala-Phe-Phe-NH_2 trifluoroacetic acid;

H-D-DMT-D-Ala-Phe-Phe-NH_2 trifluoroacetic acid salt;

H-Tyr-D-Ala-Phe-Hph-NH_2 trifluoroacetic acid salt;

H-Tyr-D-Ala-Phe-Cys(Bzl)-NH_2 trifluoroacetic acid salt;

H-Tyr-D-Arg-Hph-Phe-NH_2 bis-trifluoroacetic acid salt;

H-Tyr-D-Arg-Phg-Phe-NH_2 bis-trifluoro acetic acid salt;

H-Tyr-D-Ala-Phe-Phe-CH_2OH hydrochloride salt;

H-Tyr-D-Ala-Hph-Phe-NH_2 trifluoroacetic acid salt;

H-Tyr-D-Met-Phe-Phe-NH_2 trifluoroacetic acid salt;

H-Tyr-D-Arg-Phe-D-Phe-NH_2 bis-trifluoroacetic acid salt;

H-Tyr-D-Ala-Phg-Phe-NH_2 trifluoroacetic acid salt;

H-Tyr-(D)-Ala-(D)-Phg-Phe-NH_2 trifluoroacetic acid salt;

H-Tyr-D-Ala-Phe-Phe(pI)-NH_2 trifluoroacetic acid salt; and

H-Tyr-D-Ala-Phe-D-Phe(pF)-NH_2 trifluoroacetic acid salt.